ContraFect

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides. The company was founded by Robert Nowinski on March 5, 2008 and is headquartered in Yonkers, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

YONKERS, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that ANSM, the French National Agency for the Safety of Medicines and Health Products, has authorized its Clinical Trial Application (CTA) for the study of intra-articularly administered exebacase, in the setting of a minimally-invasive arthroscopic debridement, antibiotics, irrigation, and retention (DAIR) procedure in patients with chronic prosthetic joint infection (PJI) of the knee due to Staphylococcus aureus (S. aureus) or Coagulase-Negative Staphylococci (CoNS).

ContraFect Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

Continued execution to advance exebacase and CF-370 into new clinical studies Continued execution to advance exebacase and CF-370 into new clinical studies

ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Akero Therapeutics Inc

Astria Therapeutics

HeartBeam

Humanigen

Otonomy

Rhythm Pharmaceuticals

Vigil Neuroscience

Virios Therapeutics

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the publication of an editorial in the Journal of Bone and Joint Infection discussing the potential for each of the Company's lysins, exebacase and CF-296, as additional agents in the treatment armamentarium against bone and joint infections (BJIs) due to their in vitro activity against coagulase-negative staphylococci (CoNS), the bacteria most frequently involved in implant-associated BJIs, and their potential for both local and systemic anti-biofilm activity. The authors conclude that these advantages could compensate for the treatment challenges with current antibiotic treatments against staphylococcal BJIs alone.

ContraFect Announces Multiple Publications Highlighting the Potential Utility of Lysins for the Treatment of Bone and Joint Infections

YONKERS, N.Y., Sept. 12, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the presentation by Dr. Tristan Ferry of the Infectious and Tropical Diseases Unit, Croix-Rousse Hospital, Hôspices Civils de Lyon in Lyon, France at the 40th Annual Meeting of the European Bone and Joint Infection Society, held in Graz, Austria from September 8-10, 2022, of data from a single center, exploratory, open-label prospective study using a minimally invasive LysinDAIR procedure in patients with chronic knee prosthetic joint infection (PJI), due to coagulase-negative staphylococci (CoNS), with two different clinical presentations and treatment paradigms.

ContraFect Announces Presentation of New Clinical Data From a Study Using Exebacase in the LysinDAIR Procedure on Patients With Chronic Knee Prosthetic Joint Infection

Focused on advancement of lead programs, exebacase and CF-370, into new clinical studies Focused on advancement of lead programs, exebacase and CF-370, into new clinical studies

ContraFect Reports Second Quarter 2022 Financial Results and Provides Corporate Update

YONKERS, N.Y., Aug. 15, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today the publication of a manuscript in the Journal of Bone and Joint Infection, a leading peer-reviewed journal dedicated to the study of osteo-articular and soft-tissue infections. This manuscript presents the results from a study evaluating the activity of exebacase or the CF-296 lysin in a preclinical rabbit model of implant-associated methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. These results demonstrate that the local administration of either lysin to the affected bone, in addition to systemic antibiotics, reduced MRSA counts in the bone and on implants compared with control animals. Notably, the administration of exebacase alone, without systemic antibiotics, resulted in significant reductions in MRSA counts compared to controls. Furthermore, either exebacase or CF-296, used in addition to systemically administered daptomycin, also resulted in significant reduction in MRSA counts on infected implants compared to daptomycin alone.

ContraFect Announces Publication on Exebacase and CF-296 Demonstrating Potent In Vivo Antimicrobial Activity in Implant-Associated MRSA Osteomyelitis

A Phase 3 trial of ContraFect's treatment for antibiotic-resistant infections has been stopped, and CFRX stock is plunging. The post Why Is ContraFect (CFRX) Stock Down 80% Today?

Why Is ContraFect (CFRX) Stock Down 80% Today?

YONKERS, N.Y., July 13, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Data Safety Monitoring Board (DSMB) of the DISRUPT (Direct Lysis of Staph aureus Resistant Pathogen Trial) study has completed a pre-specified, interim futility analysis and the DSMB recommended that the trial be stopped because the conditional power of the study was below the pre-specified threshold for futility.

ContraFect Announces Independent DSMB Recommends Exebacase Phase 3 DISRUPT Study Be Stopped for Futility Following Interim Analysis

YONKERS, N.Y., June 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today presentation data showing that the Company's lead product candidate, exebacase, which has been designated as a Breakthrough Therapy for development as a treatment for methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections by the FDA, was effective in a rabbit model of implant-associated osteomyelitis. Additional data was also presented which further supports that exebacase has a low propensity for the development of antimicrobial resistance, and also has the ability to suppress antibiotic resistance to standard of care antibiotics in vitro. These data were recently presented at the ASM Microbe Conference held in Washington, D.C. from June 9-13, 2022.

Presentations at ASM Microbe Conference Demonstrate Potential of ContraFect's Direct Lytic Agents (DLAs) to Address MRSA Infections

Bluejay Diagnostics

Wejo Group Ltd

Penny stocks to buy according to analysts. The post Penny Stocks To Buy Today?

Penny Stocks To Buy Today? 3 To Watch With Analyst Targets Up To 675%

Arbutus Biopharma

Eiger BioPharmaceuticals

IVERIC bio Inc

Eli Lilly

Pfizer

SQZ Biotechnologies

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.

Biopharmaceutical Stocks: The Bottoming Process Is Playing Out

YONKERS, N.Y., June 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected to present two posters at the ASM Microbe Conference to be held in Washington, D.C. from June 9-13, 2022. The data being presented features the Company's Breakthrough Therapy designated product candidate, exebacase, currently being studied in a pivotal Phase 3 superiority design trial.

ContraFect to Present Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Combat MRSA at ASM Microbe 2022

YONKERS, N.Y., May 20, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) (ContraFect), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that on May 16, 2022, the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock option awards to purchase an aggregate of 15,000 shares of its common stock to two new non-executive employees.

ContraFect Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Phase 3 DISRUPT study achieves enrollment of MRSA patients necessary for DSMB to conduct interim futility analysis Phase 3 DISRUPT study achieves enrollment of MRSA patients necessary for DSMB to conduct interim futility analysis

ContraFect Reports First Quarter 2022 Financial Results and Provides Business Update

Oral Session Demonstrates CF-370's Potent Activity in a Rabbit Pneumonia Model of an Extensively-Resistant Pseudomonas aeruginosa Infection Oral Session Demonstrates CF-370's Potent Activity in a Rabbit Pneumonia Model of an Extensively-Resistant Pseudomonas aeruginosa Infection

ContraFect Data Presentations at the 32nd Annual ECCMID Meeting Highlight the Potential of Engineered Lysin CF-370 to Improve Clinical Outcomes and Suppress Antimicrobial Resistance Compared to Antibiotics Alone

YONKERS, N.Y., April 18, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that the Company has been selected for an oral presentation and six poster presentations at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting to be held from April 23-26, 2022 in Lisbon, Portugal. The data being presented will feature exebacase, the Company's Breakthrough Therapy designated product candidate currently being studied in a pivotal Phase 3 superiority design study, CF-370, an engineered lysin product candidate demonstrating potent in vitro bactericidal activity against resistant Gram-negative pathogens, as well as lead compounds from the Company's proprietary amurin peptide program.

ContraFect Announces Multiple Presentations of New Data Demonstrating the Potential of Its Direct Lytic Agents (DLAs) to Address Antimicrobial Resistance at the 32nd Annual ECCMID Meeting

Phase 3 DISRUPT study enrollment continues on course towards conducting interim futility analysis as anticipated in H1 2022 Phase 3 DISRUPT study enrollment continues on course towards conducting interim futility analysis as anticipated in H1 2022

ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update

YONKERS, N.Y., March 21, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the Maxim Group 2022 Virtual Growth Conference, which is being held virtually from March 28–30, 2022. The live fireside chat will be with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group on Monday, March 28, 2022 at 2:00pm ET.

ContraFect to Present at the Maxim Group 2022 Virtual Growth Conference

YONKERS, N.Y., Feb. 10, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announces today that Roger Pomerantz, M.D., President, Chief Executive Officer and Chairman of ContraFect, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference, which is being held virtually from February 14–18, 2022. The fireside chat will be held on Thursday, February 17, 2022 at 10:00 AM ET.

ContraFect to Present at the SVB Leerink 11th Annual Global Healthcare Conference

YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announces that it has received an additional award from the Cystic Fibrosis Foundation (CFF). This contract award will support investigation of the potential utility of exebacase for treating serious lung infections caused by methicillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis (CF). The program, titled Nonclinical Assessment of Lysin Exebacase for Treating MRSA Infections in CF will, over the course of 12 months, evaluate the in vitro activity of exebacase against bacterial specimens obtained from CF patients.

ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Serious MRSA Lung Infections Associated with Cystic Fibrosis

Data from Single Pediatric Patient Highlights that FDA-Designated Breakthrough Therapy Exebacase May be a Beneficial Adjunctive Therapy for Severe MRSA Infections in Children Data from Single Pediatric Patient Highlights that FDA-Designated Breakthrough Therapy Exebacase May be a Beneficial Adjunctive Therapy for Severe MRSA Infections in Children

Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRSA Bacteremia in Pediatric Populations Published in Clinical Infectious Diseases

YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced financial results and business updates for the third quarter ended September 30, 2021.

ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Company's Direct Lytic Agents Lysin CF-370 and Amurin Peptide AM1 Show In Vitro Activity Against Prevalent Gram-Negative Pathogens Associated with Lung Infections in Patients with Cystic Fibrosis Company's Direct Lytic Agents Lysin CF-370 and Amurin Peptide AM1 Show In Vitro Activity Against Prevalent Gram-Negative Pathogens Associated with Lung Infections in Patients with Cystic Fibrosis

ContraFect's New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections in Patients with Cystic Fibrosis

YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces it will be presenting a poster on the activity of DLAs against common Gram-negative pathogens responsible for pulmonary infections in Cystic Fibrosis patients at the North American Cystic Fibrosis Conference, which will be held virtually from November 2-5, 2021.

ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients

News for ContraFect Stock (CFRX)